EGFR and glioblastoma: In a phase I study using an EGFRvIII-specific CAR to treat GBM, a single dose of the CAR T cells resulted in downregulation of the EGFR/EGFRvIII receptor and appeared to promote T cell resistance, although administration was shown to be safe and potentially effective (83).